✦ LIBER ✦

Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors

✍ Scribed by William S. Messer Jr.; W.G. Rajeswaran; Yang Cao; Hai-Jun Zhang; Afif A. El-Assadi; Colleen Dockery; Jill Liske; John O'Brien; Frederick E. Williams; Xi-Ping Huang; Mary E. Wroblewski; Peter I. Nagy; Steven M. Peseckis

Book ID: 114074278
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 143 KB
Volume: 74
Category: Article
ISSN: 0031-6865
DOI: 10.1016/s0031-6865(99)00026-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of M1 subtype selective musc

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se

[Pharmacochemistry Library] Receptor Che

[Pharmacochemistry Library] Receptor Chemistry towards the Third Millennium, Proceedings of the 12th Camerino-Noordwijkerhout Symposium Volume 31 || Design and development of selective muscarinic agonists for the treatment of alzheimer's disease: characterization of tetrahydropyrimidine derivatives and dev

✍ Messer, William S. 📂 Article 📅 2000 🏛 Elsevier 🌐 English ⚖ 665 KB

*Receptor Chemistry Towards the Third Millennium* is the result of papers presented at the 12th Camerino-Noordwijkerhout Symposium, held in Camerino, Italy in September 1999. Although much is known about the way ligands interact with receptors, which have now been isolated, characterized and cloned,

Development of 5-(3-alkenyl-1,2,4-oxadia

Development of 5-(3-alkenyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine derivatives as selective muscarinic agonists for the treatment of Alzheimer's disease

✍ H. Zhang; B. Ojo; X.-P. Huang; M.A.N. Edgar; A.A. El-Assadi; D. Baril; K. Lynch; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 115 KB

Development of CDD-0102 as a selective M

Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease

✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope

Orally active and selective benzylidene

Orally active and selective benzylidene ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease

✍ Craig D. Boyle; Jean E. Lachowicz 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Use of an M1/M4-selective muscarinic ago

Use of an M1/M4-selective muscarinic agonist in combination with a peripheral antagonist as a novel approach for the treatment of Alzheimer's disease

✍ Hanson, Seth A.; Verdone, Melinda L.; Hendrickson, Michael L.; Ockuly, Jeffrey C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 40 KB